uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026)
uniQure's (QURE) quarterly Liabilities and Shareholders Equity came in at $778.7 million in Q1 2026, up 28.63% year-on-year from $605.4 million in Q1 2025, and down 5.6% quarter-over-quarter from $824.9 million in Q4 2025.
uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
uniQure's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $778.7 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 28.63% year-over-year to $778.7 million in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 21.2% increase from a year earlier, with the FY2025 full-year figure at $824.9 million, up 48.22% from the prior year.
- Liabilities and Shareholders Equity fell to $778.7 million in Q1 2026 per QURE's latest filing, from $824.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $942.8 million in Q2 2023 and bottomed at $556.5 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $730.8 million (2024), against an average of $733.2 million.
- Across the five-year window, Liabilities and Shareholders Equity soared 108.09% in 2022 and plunged 33.08% in 2024, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $705.0 million in 2022, then increased by 17.98% to $831.7 million in 2023, then plunged by 33.08% to $556.5 million in 2024, then soared by 48.22% to $824.9 million in 2025, then retreated by 5.6% to $778.7 million in 2026.
- Per Business Quant, the three latest QURE Liabilities and Shareholders Equity figures stand at $778.7 million (Q1 2026), $824.9 million (Q4 2025), and $888.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | uniQure | 2.47 Bn | 2.47 Bn | 3.34 Mn | 778.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 778.71 Mn |
| Dec 31, 2025 | 824.91 Mn |
| Sep 30, 2025 | 888.38 Mn |
| Jun 30, 2025 | 584.89 Mn |
| Mar 31, 2025 | 605.40 Mn |
| Dec 31, 2024 | 556.54 Mn |
| Sep 30, 2024 | 645.81 Mn |
| Jun 30, 2024 | 730.85 Mn |
| Mar 31, 2024 | 770.05 Mn |
| Dec 31, 2023 | 831.69 Mn |
| Sep 30, 2023 | 871.55 Mn |
| Jun 30, 2023 | 942.77 Mn |
| Mar 31, 2023 | 631.00 Mn |
| Dec 31, 2022 | 704.96 Mn |
| Sep 30, 2022 | 638.23 Mn |
| Jun 30, 2022 | 701.21 Mn |
| Mar 31, 2022 | 757.15 Mn |
| Dec 31, 2021 | 809.18 Mn |
| Sep 30, 2021 | 774.63 Mn |
| Jun 30, 2021 | 784.26 Mn |